These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 1322381)
1. Modifications of an immunodominant peptide antigen induce different anti-polyoma tumor responses in two separate mouse strains. Reinholdsson-Ljunggren G; Dalianis T Int J Cancer; 1992 Jul; 51(6):968-72. PubMed ID: 1322381 [TBL] [Abstract][Full Text] [Related]
2. Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens. Reinholdsson-Ljunggren G; Ramqvist T; Ahrlund-Richter L; Dalianis T Int J Cancer; 1992 Jan; 50(1):142-6. PubMed ID: 1370225 [TBL] [Abstract][Full Text] [Related]
3. Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein. Lukacher AE; Wilson CS J Immunol; 1998 Feb; 160(4):1724-34. PubMed ID: 9469430 [TBL] [Abstract][Full Text] [Related]
4. Polyoma virus-induced tumor-specific transplantation antigen (TSTA) is a mouse and rat cross-species-reacting antigen. Ramqvist T; Dalianis T Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1557-60. PubMed ID: 6094200 [No Abstract] [Full Text] [Related]
5. A single peptide derived from the sequence common to polyoma small and middle T-antigen induces immunity against polyoma tumors. Ramqvist T; Reinholdsson G; Carlquist M; Bergman T; Dalianis T Virology; 1989 Sep; 172(1):359-62. PubMed ID: 2475972 [TBL] [Abstract][Full Text] [Related]
6. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL. Wilson CS; Moser JM; Altman JD; Jensen PE; Lukacher AE J Immunol; 1999 Apr; 162(7):3933-41. PubMed ID: 10201912 [TBL] [Abstract][Full Text] [Related]
8. Immunization against the polyoma tumor-specific transplantation antigen (TSTA) with polyoma T-antigens. Ramqvist T; Pallas DO; DeAnda J; Ahrlund-Richter L; Reinholdsson G; Roberts TM; Schaffhausen BS; Dalianis T Int J Cancer; 1988 Jul; 42(1):123-8. PubMed ID: 2839427 [TBL] [Abstract][Full Text] [Related]
9. A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity. Berke Z; Palmer S; Bergman T; Wester D; Svedmyr J; Linder S; Jornvall H; Dalianis T J Virol; 1996 May; 70(5):3093-7. PubMed ID: 8627788 [TBL] [Abstract][Full Text] [Related]
10. Delayed hypersensitivity to polyoma and "self" antigens in syngeneic mice. Ochałek T; Burzyński A; Cadel Z; Chłap Z; Porwit-Bóbr Z Neoplasma; 1987; 34(4):441-51. PubMed ID: 2821418 [TBL] [Abstract][Full Text] [Related]
11. Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection. Lukacher AE; Moser JM; Hadley A; Altman JD J Immunol; 1999 Sep; 163(6):3369-78. PubMed ID: 10477607 [TBL] [Abstract][Full Text] [Related]
12. Immunization against the polyoma virus-induced tumor-specific transplantation antigen by early region mutants of the virus. Dalianis T; Magnusson G; Ito Y; Klein G J Virol; 1982 Sep; 43(3):772-7. PubMed ID: 6292460 [TBL] [Abstract][Full Text] [Related]
13. Identification of immunodominant epitope of F1 antigen of Yersinia pestis. Sabhnani L; Rao DN FEMS Immunol Med Microbiol; 2000 Feb; 27(2):155-62. PubMed ID: 10640611 [TBL] [Abstract][Full Text] [Related]
14. Studies on the polyoma virus tumor-specific transplantation antigen (TSTA). Dalianis T Adv Cancer Res; 1990; 55():57-85. PubMed ID: 1696775 [No Abstract] [Full Text] [Related]
15. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Newmaster RS; Mylin LM; Fu TM; Tevethia SS Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511 [TBL] [Abstract][Full Text] [Related]
16. Vaccination against polyoma virus (PyV) tumors using vaccinia-PyV recombinants: a major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein. Kieny MP; Gautier C; Tomasetto C; Kuhn I; Hareuveni M; Clertant P; Lathe R Int J Cancer; 1990 Jan; 45(1):185-9. PubMed ID: 1688831 [TBL] [Abstract][Full Text] [Related]
17. Stimulation of pp60c-src tyrosyl kinase activity in polyoma virus-infected mouse cells is closely associated with polyoma middle tumor antigen synthesis. Bolen JB; Lewis AM; Israel MA J Cell Biochem; 1985; 27(2):157-67. PubMed ID: 2580850 [TBL] [Abstract][Full Text] [Related]
18. Detection of polyoma-virus-induced tumor antigen(s) by macrophage migration inhibition. Szigeti R; Dalianis T; Klein G; Ito Y; Magnusson G Int J Cancer; 1982 Jul; 30(1):69-74. PubMed ID: 6288580 [No Abstract] [Full Text] [Related]
19. Fine specificity of the murine immune response to SV40 large tumour antigen utilizing synthetic peptides that define selected epitopes. Bright RK; Shearer MH; Kennedy RC Clin Exp Immunol; 1994 Jun; 96(3):491-9. PubMed ID: 7516272 [TBL] [Abstract][Full Text] [Related]
20. Divergence between delayed-type hypersensitivity (DTH) to polyoma tumor-associated antigen and antitumor efficacy in polyoma-bearing recipients of therapeutic non-cytolytic, DTH-mediating lymphocytes. Ochalek T Immunol Lett; 1993 Oct; 38(2):97-102. PubMed ID: 8294146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]